Brief: Vistagen Announces Completion Of Last Patient Visit In Palisade-4 Phase 3 Public Speaking Challenge Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder
08/05/2026 12:30
May 8 (Reuters) - VistaGen Therapeutics Inc VTGN.O: VISTAGEN ANNOUNCES COMPLETION OF LAST PATIENT VISIT IN PALISADE-4 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER VISTAGEN THERAPEUTICS INC - OPEN LABEL EXTENSION OF PALISADE-4 STUDY REMAINS ONGOING VISTAGEN THERAPEUTICS INC - TOPLINE RESULTS FOR PALISADE-4 RANDOMIZED PORTION EXPECTED IN Q2 2026 Source text: ID:nBw7sLn3qa Further company coverage: VTGN.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors